Hemex has successfully closed a second tranche of its Series C financing round, further details of which can be found in a press release. In so doing, the company for clinical contract research and investments in start-ups active in the healthcare industry has so far raised a total of 7.1 million Swiss francs in the year to date.
Hemex, a partner of the investment and innovation promotion agency Basel Area Business & Innovation, intends to use this fresh capital injection to finance initial investments in early-phase start-ups active in the field of life sciences. Moreover, the company, which is based in Liestal in the canton of Basel-Landschaft, will seek to recruit new team members for clinical activities, quality assurance and regulatory matters.
The support from both existing and new investors “shows the potential of our business model”, comments co-founder and CEO Pascal Winnen in the press release. “With our fast-growing team of highly qualified healthcare professionals as well as a strong network of specialized consultants, we will continue to offer our shareholders the opportunity to identify and invest in early-stage healthcare start-ups, with active management of the portfolio”, he adds.
